Gal Rubinstein
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Gal Rubinstein has a total of 87 co-authors. Here are the top co-authors by number of shared publications:
Farhana Latif
Division of Cardiology, Department of Medicine Columbia University Irving Medical Center New York New York USA
7 shared publicationsAndrea Fernandez Valledor
Department of Medicine Division of Cardiology, New York Presbyterian Hospital/Columbia University Irving Medical Center New York New York USA
6 shared publicationsGabriel T. Sayer
Division of Cardiology, Department of Medicine Columbia University Irving Medical Center New York New York USA
6 shared publicationsJustin A. Fried
Division of Cardiology, Department of Medicine Columbia University Irving Medical Center New York New York USA
6 shared publicationsNir Uriel
Division of Cardiology, Department of Medicine Columbia University Irving Medical Center New York New York USA
6 shared publications- Cathrine M. Moeller
Division of Cardiology, Advanced Cardiac Care, Columbia University Irving Medical Center, New York, NY
5 shared publications
Latest Publications
- 14 October 2025
- Published by Wiley in Clinical Transplantation
- Vol. 39 (10) , e70340
Clinical Utility of Combined Donor‐Derived Cell‐Free DNA and Peripheral Gene‐Expression‐Profiling in Heart Transplant Recipients
Introduction: Donor‐derived‐cell‐free‐DNA (dd‐cfDNA) and peripheral‐gene‐expression‐profiling (pGEP) are tools for monitoring heart transplant (HT) recipients for rejection. We aimed to assess the combined utility of dd‐cfDNA/pGEP in HT recipients. Methods: We evaluated HT recipients between 2019 and 2023 with a paired dd‐cfDNA(AlloSure‐AS)/GEP(AlloMap‐AM) results (HeartCare‐CareDx‐CA‐USA). Multi‐organ‐transplant recipients were excluded. Samples were assessed with endomyocardial biopsy 0. A positive GEP test score was defined as >30 within 5 months posttransplant and 34 thereafter; a positive dd‐cfDNA result was ≥0.12%. Samples were categorized into four groups based on dd‐cfDNA/GEP results. Results: Of the 2388 samples (257 patients) included, 1437 samples (60.2%) were (−)dd‐cfDNA/(−)GEP, 419 samples (17.5%) were (−)dd‐cfDNA/(+)GEP, 375 samples (15.7%) were (+)dd‐cfDNA/(−)GEP, and 157 samples (6.6%) were (+)dd‐cfDNA/(+)GEP. The median age was 55 years and 27% were females. The median time from HT to sample was 10 months [IQR 5–18]. The median positive AS level was 0.22% [IQR 0.15–0.48]. Twenty‐nine percent of the samples had correlated EMB results, mostly in the (+)dd‐cfDNA/(+)GEP group (55%), followed by the discordant groups (+)dd‐cfDNA/(−)GEP (49%) and (−)dd‐cfDNA/(+)GEP (32%), and the (−)dd‐cfDNA/(−)GEP group (20%; p < 0.001). Rejection occurred in 7.1% of samples, with the highest rates in the (+)dd‐cfDNA/(+)GEP group (15.1%), followed by the (+)dd‐cfDNA/(−)GEP (10.9%), (−)dd‐cfDNA/(−)GEP (3.8%), and (−)dd‐cfDNA/(+)GEP (3.7%) ( p < 0.001) groups. The median follow‐up time was 29 months [IQR 16–42]. The (+)dd‐cfDNA/(+)GEP group demonstrated an increased risk of mortality (HR: 6.1, 95% CI [2.5–14.8]; p < 0.001) compared to (−)dd‐cfDNA/(−)GEP group. Similarly the (+)dd‐cfDNA/(−)GEP group demonstrated an almost 6‐fold risk of mortality (HR: 5.6, 95% CI [1.8–17.5]; p = 0.003). Conclusions: Patients with (+)dd‐cfDNA/(+)GEP result were more frequently biopsied and had higher rates of rejection. This group exhibited a six‐fold increased risk of mortality and a seven‐fold increased risk of mortality at dd‐cfDNA thresholds of 0.12% and 0.20%, respectively, compared to the negative concordant group.
- 14 October 2025
- Published by Wiley in Clinical Transplantation
- Vol. 39 (10) , e70340
Clinical Utility of Combined Donor‐Derived Cell‐Free DNA and Peripheral Gene‐Expression‐Profiling in Heart Transplant Recipients
Introduction: Donor‐derived‐cell‐free‐DNA (dd‐cfDNA) and peripheral‐gene‐expression‐profiling (pGEP) are tools for monitoring heart transplant (HT) recipients for rejection. We aimed to assess the combined utility of dd‐cfDNA/pGEP in HT recipients. Methods: We evaluated HT recipients between 2019 and 2023 with a paired dd‐cfDNA(AlloSure‐AS)/GEP(AlloMap‐AM) results (HeartCare‐CareDx‐CA‐USA). Multi‐organ‐transplant recipients were excluded. Samples were assessed with endomyocardial biopsy 0. A positive GEP test score was defined as >30 within 5 months posttransplant and 34 thereafter; a positive dd‐cfDNA result was ≥0.12%. Samples were categorized into four groups based on dd‐cfDNA/GEP results. Results: Of the 2388 samples (257 patients) included, 1437 samples (60.2%) were (−)dd‐cfDNA/(−)GEP, 419 samples (17.5%) were (−)dd‐cfDNA/(+)GEP, 375 samples (15.7%) were (+)dd‐cfDNA/(−)GEP, and 157 samples (6.6%) were (+)dd‐cfDNA/(+)GEP. The median age was 55 years and 27% were females. The median time from HT to sample was 10 months [IQR 5–18]. The median positive AS level was 0.22% [IQR 0.15–0.48]. Twenty‐nine percent of the samples had correlated EMB results, mostly in the (+)dd‐cfDNA/(+)GEP group (55%), followed by the discordant groups (+)dd‐cfDNA/(−)GEP (49%) and (−)dd‐cfDNA/(+)GEP (32%), and the (−)dd‐cfDNA/(−)GEP group (20%; p < 0.001). Rejection occurred in 7.1% of samples, with the highest rates in the (+)dd‐cfDNA/(+)GEP group (15.1%), followed by the (+)dd‐cfDNA/(−)GEP (10.9%), (−)dd‐cfDNA/(−)GEP (3.8%), and (−)dd‐cfDNA/(+)GEP (3.7%) ( p < 0.001) groups. The median follow‐up time was 29 months [IQR 16–42]. The (+)dd‐cfDNA/(+)GEP group demonstrated an increased risk of mortality (HR: 6.1, 95% CI [2.5–14.8]; p < 0.001) compared to (−)dd‐cfDNA/(−)GEP group. Similarly the (+)dd‐cfDNA/(−)GEP group demonstrated an almost 6‐fold risk of mortality (HR: 5.6, 95% CI [1.8–17.5]; p = 0.003). Conclusions: Patients with (+)dd‐cfDNA/(+)GEP result were more frequently biopsied and had higher rates of rejection. This group exhibited a six‐fold increased risk of mortality and a seven‐fold increased risk of mortality at dd‐cfDNA thresholds of 0.12% and 0.20%, respectively, compared to the negative concordant group.
- 23 July 2025
- Published by Wiley in Clinical Transplantation
- Vol. 39 (8) , e70247
Extracorporeal Photopheresis in the Treatment of Cardiac Allograft Rejection in the Modern Era: A Single‐Center Experience
Background: Extracorporeal photopheresis (ECP) has gained recognition as a valuable adjunctive antirejection therapy, particularly in heart‐transplantation (HT) patients at elevated risk for rejection or those experiencing recurrent antibody‐mediated rejection (AMR) despite appropriate treatment. We evaluated the safety and clinical effects of ECP in HT recipients with high immunologic risk. Methods: All HT recipients who underwent ECP between February 2020 and January 2024 were included in this retrospective, single‐center study. Results: Fifteen patients who underwent ECP were identified. Twelve patients completed ECP and were followed for a median of 11.2 months (3.9–19.9). The time from transplant to ECP initiation was 5.3 years (1.3–13). The most common indication for ECP was AMR (60%). During ECP, immunosuppression regimens were maintained or de‐escalated in 93% of the patients. Reduction in donor specific antibodies (DSA), peripheral gene expression profiling (GEP), and donor‐derived cell‐free DNA (dd‐cfDNA) levels were observed in 64%, 57%, and 67% of the patients, respectively. Eighty‐three percent of the patients were free from rejection during the follow‐up period. Overall survival was 87%, and no deaths were related to ECP. Conclusion: In our single‐center experience, ECP resulted in a decrease in immunosuppression use, and a reduction in DSA, GEP, and dd‐cfDNA levels with a high freedom‐from‐rejection rate.
- 23 July 2025
- Published by Wiley in Clinical Transplantation
- Vol. 39 (8) , e70247
Extracorporeal Photopheresis in the Treatment of Cardiac Allograft Rejection in the Modern Era: A Single‐Center Experience
Background: Extracorporeal photopheresis (ECP) has gained recognition as a valuable adjunctive antirejection therapy, particularly in heart‐transplantation (HT) patients at elevated risk for rejection or those experiencing recurrent antibody‐mediated rejection (AMR) despite appropriate treatment. We evaluated the safety and clinical effects of ECP in HT recipients with high immunologic risk. Methods: All HT recipients who underwent ECP between February 2020 and January 2024 were included in this retrospective, single‐center study. Results: Fifteen patients who underwent ECP were identified. Twelve patients completed ECP and were followed for a median of 11.2 months (3.9–19.9). The time from transplant to ECP initiation was 5.3 years (1.3–13). The most common indication for ECP was AMR (60%). During ECP, immunosuppression regimens were maintained or de‐escalated in 93% of the patients. Reduction in donor specific antibodies (DSA), peripheral gene expression profiling (GEP), and donor‐derived cell‐free DNA (dd‐cfDNA) levels were observed in 64%, 57%, and 67% of the patients, respectively. Eighty‐three percent of the patients were free from rejection during the follow‐up period. Overall survival was 87%, and no deaths were related to ECP. Conclusion: In our single‐center experience, ECP resulted in a decrease in immunosuppression use, and a reduction in DSA, GEP, and dd‐cfDNA levels with a high freedom‐from‐rejection rate.
- 13 May 2025
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 44 (9) , 1384-1393
Correlation between donor-derived cell-free DNA and tissue gene expression in heart transplant patients undergoing for-cause endomyocardial biopsies
- 13 May 2025
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 44 (9) , 1384-1393
Correlation between donor-derived cell-free DNA and tissue gene expression in heart transplant patients undergoing for-cause endomyocardial biopsies
- 1 January 2025
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 18 (1) , e011756
Elevated Donor-Derived Cell-Free DNA Levels Are Associated With Reduced Myocardial Blood Flow but Not Angiographic Cardiac Allograft Vasculopathy: The EVIDENT Study
BACKGROUND: Cardiac allograft vasculopathy (CAV) leads to impaired myocardial blood flow (MBF), increasing the risk of cardiovascular death or retransplant among heart transplantation (HT) recipients. Data on elevation in donor-derived cell-free DNA (dd-cfDNA) and CAV in the absence of rejection are mixed. We sought to test the hypothesis that CAV with reduced MBF (RMBF) is associated with elevated dd-cfDNA. METHODS: A retrospective review was conducted on HT recipients at a high-volume center who underwent dd-cfDNA testing between September 2019 and November 2022. Inclusion criteria included undergoing CAV screening with cardiac positron emission tomography scans and coronary angiograms. Patients were grouped by the presence of angiographic CAV diagnosis and MBF reserve evaluated through cardiac positron emission tomography. The latter was subdivided into normal MBF or RMBF, with RMBF defined as an MBF reserve ≤2. Elevated dd-cfDNA was defined as ≥0.12%. RESULTS: Two hundred fifty-six HT recipients were included (median age, 55 years; 27.6% female; median, 8 years [interquartile range (IQR), 5–14] post-HT). Ischemic etiology of heart failure was more prevalent in the RMBF group (36%) compared with the normal MBF group (20%; P =0.02). The prevalence and magnitude of a positive dd-cfDNA test with angiographic CAV (29%; median, 0.26% [IQR, 0.15%–0.62%]) were not significantly different from those without CAV (30%; P =0.94; median, 0.31% [IQR, 0.17%–0.71%]; P =0.38). However, RMBF patients exhibited significantly higher dd-cfDNA prevalence and levels (51%; median, 0.81% [IQR, 0.48%–1.11%]) compared with normal MBF patients (27%; P P <0.001). CONCLUSIONS: HT recipients with angiographic CAV had similar dd-cfDNA levels and rates as those without. Notably, dd-cfDNA levels and rates were significantly elevated in patients with RMBF assessed by positron emission tomography compared with those with normal MBF.
- 1 January 2025
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 18 (1) , e011756
Elevated Donor-Derived Cell-Free DNA Levels Are Associated With Reduced Myocardial Blood Flow but Not Angiographic Cardiac Allograft Vasculopathy: The EVIDENT Study
BACKGROUND: Cardiac allograft vasculopathy (CAV) leads to impaired myocardial blood flow (MBF), increasing the risk of cardiovascular death or retransplant among heart transplantation (HT) recipients. Data on elevation in donor-derived cell-free DNA (dd-cfDNA) and CAV in the absence of rejection are mixed. We sought to test the hypothesis that CAV with reduced MBF (RMBF) is associated with elevated dd-cfDNA. METHODS: A retrospective review was conducted on HT recipients at a high-volume center who underwent dd-cfDNA testing between September 2019 and November 2022. Inclusion criteria included undergoing CAV screening with cardiac positron emission tomography scans and coronary angiograms. Patients were grouped by the presence of angiographic CAV diagnosis and MBF reserve evaluated through cardiac positron emission tomography. The latter was subdivided into normal MBF or RMBF, with RMBF defined as an MBF reserve ≤2. Elevated dd-cfDNA was defined as ≥0.12%. RESULTS: Two hundred fifty-six HT recipients were included (median age, 55 years; 27.6% female; median, 8 years [interquartile range (IQR), 5–14] post-HT). Ischemic etiology of heart failure was more prevalent in the RMBF group (36%) compared with the normal MBF group (20%; P =0.02). The prevalence and magnitude of a positive dd-cfDNA test with angiographic CAV (29%; median, 0.26% [IQR, 0.15%–0.62%]) were not significantly different from those without CAV (30%; P =0.94; median, 0.31% [IQR, 0.17%–0.71%]; P =0.38). However, RMBF patients exhibited significantly higher dd-cfDNA prevalence and levels (51%; median, 0.81% [IQR, 0.48%–1.11%]) compared with normal MBF patients (27%; P P <0.001). CONCLUSIONS: HT recipients with angiographic CAV had similar dd-cfDNA levels and rates as those without. Notably, dd-cfDNA levels and rates were significantly elevated in patients with RMBF assessed by positron emission tomography compared with those with normal MBF.
- Open Access
- 16 October 2024
- Published by Springer Nature in Cardio-Oncology
- Vol. 10 (1) , 1-4
Recurrent melanoma 25 years after initial diagnosis, presenting as metastatic disease early after heart transplantation
Cancer survivors (CS) comprise a particularly high-risk group for both de-novo and recurrent malignancies after solid organ transplantation. We report a case of relapsed melanoma, presented as metastatic disease seven months after heart transplantation in a patient who had an early-stage melanoma resected 25 years prior. Treatment with a combination of dabrafenib, a BRAF inhibitor, and trametinib, a mitogen-activated protein kinase (MEK) inhibitor resulted in a near-complete metabolic response, without major adverse effects. This case demonstrates the increased risk of recurrence in CS with melanoma, which can persist decades after cancer diagnosis. These patients may be amenable to treatment using modern treatment modalities in oncology.
- 16 October 2024
- Published by Springer Nature in Cardio-Oncology
- Vol. 10 (1) , 1-4
Open AccessRecurrent melanoma 25 years after initial diagnosis, presenting as metastatic disease early after heart transplantation
Cancer survivors (CS) comprise a particularly high-risk group for both de-novo and recurrent malignancies after solid organ transplantation. We report a case of relapsed melanoma, presented as metastatic disease seven months after heart transplantation in a patient who had an early-stage melanoma resected 25 years prior. Treatment with a combination of dabrafenib, a BRAF inhibitor, and trametinib, a mitogen-activated protein kinase (MEK) inhibitor resulted in a near-complete metabolic response, without major adverse effects. This case demonstrates the increased risk of recurrence in CS with melanoma, which can persist decades after cancer diagnosis. These patients may be amenable to treatment using modern treatment modalities in oncology.
- 19 February 2024
- Published by Wolters Kluwer Health in ASAIO Journal
- Vol. 70 (8) , 641-650
Hemodynamic Optimization by Invasive Ramp Test in Patients Supported With HeartMate 3 Left Ventricular Assist Device
In patients supported by the HeartMate 3 left ventricular assist device (HM3 LVAD), pump speed adjustments may improve hemodynamics. We investigated the hemodynamic implications of speed adjustments in HM3 recipients undergoing hemodynamic ramp tests. Clinically stable HM3 recipients who underwent routine invasive hemodynamic ramp tests between 2015 and 2022 at our center were included. Filling pressure optimization, defined as central venous pressure (CVP) p = 0.03 for both), predominantly due to lower cardiac readmission-free rates (p = 0.052). In stable outpatients supported with HM3 who underwent routine ramp tests, optimized hemodynamics were achieved in only 2 of 3 of the patients. Patients with optimized pressures had lower all-cause readmission rates, primarily driven by fewer cardiac-related hospitalizations.
- 19 February 2024
- Published by Wolters Kluwer Health in ASAIO Journal
- Vol. 70 (8) , 641-650
Hemodynamic Optimization by Invasive Ramp Test in Patients Supported With HeartMate 3 Left Ventricular Assist Device
In patients supported by the HeartMate 3 left ventricular assist device (HM3 LVAD), pump speed adjustments may improve hemodynamics. We investigated the hemodynamic implications of speed adjustments in HM3 recipients undergoing hemodynamic ramp tests. Clinically stable HM3 recipients who underwent routine invasive hemodynamic ramp tests between 2015 and 2022 at our center were included. Filling pressure optimization, defined as central venous pressure (CVP) p = 0.03 for both), predominantly due to lower cardiac readmission-free rates (p = 0.052). In stable outpatients supported with HM3 who underwent routine ramp tests, optimized hemodynamics were achieved in only 2 of 3 of the patients. Patients with optimized pressures had lower all-cause readmission rates, primarily driven by fewer cardiac-related hospitalizations.
- 14 February 2024
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 43 (6) , 1010-1020
“Durable left ventricular assist devices as a bridge to transplantation in The Old and The New World”
- 14 February 2024
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 43 (6) , 1010-1020
“Durable left ventricular assist devices as a bridge to transplantation in The Old and The New World”
- 7 November 2023
- Published by Wolters Kluwer Health in ASAIO Journal
- Vol. 70 (6) , 461-468
Pumping for Two: Pregnancy in Patients Supported With a Left Ventricular Assist Device
This review discusses the challenges and outcomes associated with pregnancy during left ventricular assist device (LVAD) support. Women account for a third of the heart failure population in the United States. Left ventricular assist devices have emerged as a safe and effective treatment option for patients with advanced heart failure. Pregnancy during LVAD support can occur, and it presents significant risks to both mother and fetus, including hemodynamic stress, thrombotic events, medication-associated teratogenicity, and uterine impingement. This literature review identified 10 cases of confirmed pregnancy during LVAD support, of which eight resulted in successful births. Maternal and fetal mortality occurred in one case, and there was a spontaneous abortion in one case. The review highlights the importance of a multidisciplinary approach, promotion of shared decision-making, thoughtful anticoagulation, adjustment of LVAD speed, and medication optimization to maintain hemodynamic support during pregnancy. Hemodynamic changes during pregnancy include increased cardiac output, heart rate, and plasma volume, as well as decreased systemic vascular resistance, which can impact LVAD support. Despite reduced pulsatility in LVAD-supported patients, ovulation and reproductive capacity might be preserved, and viable pregnancies may be achieved with appropriate management. The review provides insights into the risks and considerations for a viable pregnancy during LVAD support, including the need for ongoing research to inform joined decision-making.
- 7 November 2023
- Published by Wolters Kluwer Health in ASAIO Journal
- Vol. 70 (6) , 461-468
Pumping for Two: Pregnancy in Patients Supported With a Left Ventricular Assist Device
This review discusses the challenges and outcomes associated with pregnancy during left ventricular assist device (LVAD) support. Women account for a third of the heart failure population in the United States. Left ventricular assist devices have emerged as a safe and effective treatment option for patients with advanced heart failure. Pregnancy during LVAD support can occur, and it presents significant risks to both mother and fetus, including hemodynamic stress, thrombotic events, medication-associated teratogenicity, and uterine impingement. This literature review identified 10 cases of confirmed pregnancy during LVAD support, of which eight resulted in successful births. Maternal and fetal mortality occurred in one case, and there was a spontaneous abortion in one case. The review highlights the importance of a multidisciplinary approach, promotion of shared decision-making, thoughtful anticoagulation, adjustment of LVAD speed, and medication optimization to maintain hemodynamic support during pregnancy. Hemodynamic changes during pregnancy include increased cardiac output, heart rate, and plasma volume, as well as decreased systemic vascular resistance, which can impact LVAD support. Despite reduced pulsatility in LVAD-supported patients, ovulation and reproductive capacity might be preserved, and viable pregnancies may be achieved with appropriate management. The review provides insights into the risks and considerations for a viable pregnancy during LVAD support, including the need for ongoing research to inform joined decision-making.
- 23 August 2023
- Published by Elsevier in Journal of Cardiac Failure
- Vol. 30 (1) , 95-99
The Hemodynamic Effects of Aortic Regurgitation in Patients Supported by a HeartMate 3 Left Ventricular Assist Device
- 23 August 2023
- Published by Elsevier in Journal of Cardiac Failure
- Vol. 30 (1) , 95-99
The Hemodynamic Effects of Aortic Regurgitation in Patients Supported by a HeartMate 3 Left Ventricular Assist Device
- 3 January 2023
- Published by Elsevier in Nutrition, Metabolism and Cardiovascular Diseases
- Vol. 33 (3) , 667-670
Combined heart and liver transplantation in a patient supported by left ventricular assist device (LVAD) with propionic acidemia
- 3 January 2023
- Published by Elsevier in Nutrition, Metabolism and Cardiovascular Diseases
- Vol. 33 (3) , 667-670
Combined heart and liver transplantation in a patient supported by left ventricular assist device (LVAD) with propionic acidemia